R ecent experimental evidence demonstrated that impaired cholesterol efflux pathways 1 and low high-density lipoprotein cholesterol (HDL-C) cause hematopoietic stem cell proliferation, especially monocytosis, and thereby drive atherosclerotic plaque progression in mice. 2 However, it is currently unknown whether these findings can be translated to humans. In this respect, chronic kidney disease (CKD) is an interesting condition to study because patients with CKD show an altered lipid metabolism, 3,4 with reduced cholesterol efflux capacity owing to low and dysfunctional HDL-C 5,6 ; at the same time, CKD is characterized by immunoactivation and, specifically, changes in monocyte biology have been found to mediate inflammation in CKD. 7, 8 Up to 3 monocyte subsets can be distinguished by flow cytometry according to differential surface expression of CD14 and CD16 in humans and of Ly6c in mice. Both species exhibit differences in chemokine receptor expression of CCR2, CCR5, and CX 3 CR1. In humans, monocytes subsets are defined as classical CD14 ++ CD16 − , intermediate CD14 ++ CD16 + , and nonclassical CD14 + CD16 ++ monocytes; the latter have been often summarized as CD16-positive monocytes. 9 In mice, Ly6c + CCR2 ++ CX 3 CR1 − monocytes are the homologues of human classical CD14 ++ CD16 − monocytes and Ly6c − CCR2 − CX 3 CR1 + monocytes are homologues of human nonclassical CD14 + CD16 ++ monocytes; furthermore, Ly6c + CCR2 ++ CX 3 CR1 − monocytes have been found to cluster with intermediate CD14 ++ CD16 + monocytes. 10 Murine monocyte subsets differentially contribute to atherogenesis, 11,12 and only recently, an outstanding role of a CCR5 + murine monocyte subset has been demonstrated in atherosclerosis. 13 A deeper discussion of monocyte heterogeneity has recently been provided in excellent reviews. 14, 15 Objective-Patients with chronic kidney disease (CKD) display impaired cholesterol efflux capacity and elevated CD14 ++ CD16 + monocyte counts. In mice, dysfunctional cholesterol efflux causes monocytosis. It is unknown whether cholesterol efflux capacity and monocyte subsets are associated in CKD.
In line with these experimental findings in rodents, epidemiological evidence suggests that CD16-positive monocytes are associated with cardiovascular risk in healthy volunteers, 16 and specifically, intermediate CD14 ++ CD16 + monocytes predict cardiovascular events in subjects at elevated cardiovascular risk. 17 Because of unknown mechanisms, declining renal function is associated with a shift toward CD16-positive monocytes, 18, 19 and CKD patients with highest counts of intermediate monocytes have worst cardiovascular outcome. 18, 20 Against this background, we now hypothesized that cholesterol handling, encompassing cellular uptake, efflux, and accumulation of cholesterol, could be associated with shifts in monocyte subsets in patients with CKD, in whom cholesterol efflux capacity is impaired due to low apolipoprotein A-I (Apo A-I) and low HDL-C.
To date, there have been no reports examining the relationship between lipid metabolism, human monocyte subsets, and cardiovascular outcomes in a CKD population.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Mediators of Cholesterol Efflux, Monocyte Subsets, and Cardiovascular Outcomes in 438 CARE FOR HOMe Participants
Monocyte subset analysis is exemplified in Figure I in the onlineonly Data Supplement. Baseline characteristics of the participants according to kidney function are summarized in Table 1 .
Mediators of cholesterol efflux (lower Apo A-I and lower HDL-C) were significantly associated with higher counts of intermediate monocytes, but not with counts of total or classical monocytes ( Table 2) . To further analyze determinants of monocyte subsets counts, we computed linear regression analyses with estimated glomerular filtration rate (eGFR), lipid parameters, and other traditional cardiovascular risk factors as independent variables. Active smoking predicted total and classical monocyte counts, whereas body mass index predicted nonclassical (and again total) monocyte counts. Interestingly, these multivariate regression analyses identified neither lipid parameters nor eGFR as predictors of total, classical, or nonclassical monocyte counts. By contrast, more advanced CKD and mediators of cholesterol efflux (lower Apo A-I [ Table 3 ] and lower HDL-C [ To analyze the potential clinical significance of low levels of cholesterol efflux mediators and cellular mediators of inflammation, we recorded the subsequent occurrence of a composite cardiovascular end point (first occurrence of acute myocardial infarction; surgical or interventional coronary/ cerebrovascular/peripheral-arterial revascularization; stroke with symptoms ≥24 hours; amputation above the ankle; or death of any cause). After a mean follow-up of 2.5±1.3 years, 81 patients experienced this end point. Those experiencing a subsequent event had lower plasma lipoproteins and higher levels of inflammatory markers (monocyte subsets and highsensitivity C-reactive protein). Strikingly, patients with a subsequent event had a 41% increase in intermediate monocyte counts but only a 10% higher classical monocyte count at baseline evaluation compared with patients without events. Further details of study participants stratified by event status are presented in Table I in the online-only Data Supplement.
To illustrate the prognostic implications of lipid metabolism and inflammation, participants were stratified into tertiles of levels of cholesterol efflux mediators (Apo A-I and HDL-C) and intermediate monocyte counts, and Kaplan-Meier survival curves were calculated. Higher intermediate monocyte counts (Figure 2A ) and lower concentrations of Apo A-I and HDL-C ( Figure 2B and 2C) were significant outcome predictors after categorization. In Kaplan-Meier analysis, neither classical nor nonclassical monocytes predicted outcome ( Figure IVa and IVb in the online-only Data Supplement).
Having found that lower levels of cholesterol efflux mediators and higher intermediate monocyte counts were associated with each other and that they predicted the end point, we finally performed Cox regression analyses that included well-known predictors of adverse outcome-prevalent diabetes mellitus, log-transformed albuminuria, age, cholesterol efflux mediators (either Apo A-I or HDL-C), low-density lipoprotein cholesterol, prevalent cardiovascular disease, eGFR, mean blood pressure, and sex-and intermediate monocyte counts. In this multivariate model, intermediate monocytes remained significant outcome predictors, whereas eGFR and plasma lipoproteins did not predict outcome. Of note, every increase of 10 intermediate monocytes/μL of blood conferred a 10% and 11% higher risk of reaching the end point in Cox regression models with Apo A-I and HDL-C, respectively ( 
Experimental Analyses of Cholesterol Handling in Monocyte Subsets
To better understand the inter-relationship between lipid metabolism and intermediate monocytes, we analyzed in more detail cellular cholesterol content and mediators of cholesterol uptake in a randomly selected subgroup of 48 CARE FOR HOMe participants who consecutively presented at the outpatient department. Finally, 2 functional assays of cellular cholesterol efflux and cytokine production were performed in a further subgroup of 6 and 8 patients with CKD, respectively, randomly selected from renal clinics (for inclusion and exclusion criteria for all patients used in this study, please see Methods in the onlineonly Data Supplement). These functional assays could not be performed on all 48 CARE FOR HOMe participants due to assay design (ie, not high throughput). 
Intracellular Lipid Content in Monocyte Subsets From Patients With CKD
Distribution of Scavenger Receptors (CD36, CD68) and of ABCA1 in Monocyte Subsets
We next asked whether monocyte subsets show different expression of crucial mediators of cellular cholesterol uptake, such as scavenger receptors CD36 and CD68, and Data are presented as numbers (percentages) or means±SD as appropriate. Values for UAE, HDL-C, Apo A-I, hsCRP, and triglycerides are given as median and interquartile range. ACE inhibitor indicates angiotensin-converting enzyme inhibitor; Apo A-I, apolipoprotein A-I; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MRA, mineralocorticoid receptor antagonist; UAE, urinary albumin excretion; and VDR-A, vitamin D receptor agonist.
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the cholesterol efflux pump ABCA1 in our subgroup of 48 patients with CKD. Interestingly, intermediate monocytes had highest expression of CD68 (P<0.001; Figure 3B ). CD36 expression on intermediate monocytes was similar to classical monocytes, but significantly higher than on nonclassical monocytes (P<0.001; Figure 3C ). Furthermore, ABCA1 expression differed between monocyte subsets (P<0.001), with lower ABCA1 expression by intermediate monocytes than by classical monocytes (P<0.001; Figure 3D ).
Cholesterol Efflux Capacity in Purified Monocyte Subsets
To further investigate the relationship between monocyte subsets and intracellular cholesterol content, we performed functional analyses of H 3 -labeled cholesterol efflux capacity in sorted monocyte subsets of 6 donors with CKD. Of note, cholesterol efflux capacity was lowest in intermediate monocytes compared with the other 2 subsets (P<0.001; Figure 4 ), providing a mechanism for preferential cholesterol accumulation in this subset.
Intracellular Cholesterol Content and Intracellular Cytokine Production in Monocyte Subsets After Oxidized Low-Density Lipoprotein Cholesterol Stimulation
Finally, we determined the monocyte subsets' response to oxidized low-density lipoprotein cholesterol, which is an established driver of atherosclerosis 15 in blood obtained from 8 donors with CKD. After stimulation with oxidized low-density lipoprotein cholesterol, intermediate monocytes displayed highest intracellular BODIPY content (P<0.01; Figure 5A ). Additionally, we observed a commensurate increase in intracellular proinflammatory cytokines interleukin (IL)-6, tumor necrosis factor-α, and IL-1β, which was most pronounced in intermediate monocytes (IL-6, P<0.05; tumor necrosis factor-α, P<0.001; IL-1β, P<0.05; Figure 5B 
Discussion
Investigating monocyte heterogeneity in a large cohort of patients with CKD, we discovered an inter-relationship between low concentrations of cholesterol efflux mediators (low Apo A-I and low HDL-C), higher intermediate monocyte counts, and cardiovascular outcomes. Of note, our Cox regression analyses suggest that intermediate monocytes provide a significant insight over traditional risk factors on the prediction of cardiovascular events in patients with CKD.
When further probing the inter-relationship between cholesterol metabolism and intermediate monocytes, we found rather selective lipid enrichment in intermediate monocytes. This finding may be explained by the differential endowment of monocyte subsets with scavenger receptors and efflux pumps. Intermediate monocytes had higher CD68, similar CD36, and significantly lower ABCA1 expression than Correlation coefficients between monocyte (subset) counts (in cells/μL) and lipid parameters. Apo A-I indicates apolipoprotein A-I; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.
Arterioscler Thromb Vasc Biol
September 2014 classical monocytes in our CKD cohort. In functional analyses, intermediate monocytes had the lowest capacity to efflux cholesterol. Moreover, intermediate monocytes avidly took up oxidized low-density lipoprotein cholesterol and subsequently had highest intracellular proinflammatory cytokine production of all 3 monocyte subsets. Impaired cholesterol efflux capacity, owing to low 21 and dysfunctional 5,6,22,23 HDL-C, could be an important mediator of immunoactivation 22, 23 and resulting cardiovascular disease in CKD because cholesterol efflux was shown to regulate monocytopoiesis in mice. 2 In keeping with these experimental results and animal data, a recent analysis of the Malmo Diet and Cancer Study in the general population described an association between HDL-C levels and cells of the myeloid lineage, that is, monocytes, basophils, and eosinophils, which was dependent on renal function. 24 However, neither murine studies 2 nor the Malmo Diet and Cancer study addressed a potential relationship between mediators of cholesterol efflux (Apo A-I and HDL-C) and monocyte heterogeneity, which comprises 3 human monocyte subsets: classical CD14 ++ CD16 − , intermediate CD14 ++ CD16 + , and nonclassical CD14 + CD16 ++ monocytes. 9 Specific characteristics 25, 26 of intermediate monocytes probably account for their relation with cardiovascular outcomes.
First, intermediate monocytes have highest expression of CCR5 alongside high expression of CCR2 and fractalkine receptor (CX 3 CR1), 20, 27 comprising a chemokine receptor triad of well-established relevance in atherosclerosis. 28 Specifically, the outstanding role of CCR5 has been established by Braunersreuther et al 29 who demonstrated that although CCR1 and CCR5 both mediate monocyte interaction with CCL5, which is expressed in atherosclerotic plaques, genetic deletion specifically of CCR5 but not of CCR1 protects against experimental atherogenesis. In an elegant experimental study, the role of CCR5 has been recently further underscored 13 ; additional support derives from single nucleotide polymorphism studies demonstrating the CCR5 Δ32 variant to be protective in cardiovascular disease 30 and by the efficacy of maraviroc, a -I; B) , and tertiles of HDL-C (C) and event-free survival, followed by log-rank test; n=438 patients with CKD.
CCR5 antagonist, for preventing atherosclerotic plaque development in an apoE mouse model. 31 Second, intermediate monocytes have the highest inflammatory capacity among monocyte subsets as evidenced by rather selective tumor necrosis factor-α and IL-1β secretion upon stimulation 10 and highest reactive oxygen species production, 26 further accompanied by high angiotensin-converting enzyme expression, the up-regulation of which has been associated with poor outcome in patients with CKD. 32 Third, although virtually all studies in mice analyzed only 2 major monocyte subsets, clustering analyses link human intermediate monocytes to murine proinflammatory Gr1 + monocytes 10 that have been identified as the dominant monocyte subset in murine models of atherosclerosis. [11] [12] [13] Finally, our finding of lipid accumulation in intermediate monocytes may be of great importance because experimental studies found intracellular cholesterol accumulation to trigger inflammation by activating the inflammasome 33 
Study Strengths and Limitations
The rationale for our study is well founded by elegant animal models. We now translate these findings to human pathophysiology and provide evidence for their clinical relevance. Of note, the present study is the largest study to date that has evaluated monocyte heterogeneity in patients with CKD, providing a solid base for our findings. In addition, monocyte subset analysis has been done blinded to patients' clinical characteristics and vice versa outcome adjudication was blinded to baseline monocyte subset distribution status. As a limitation, lipid parameters have to be interpreted as on-treatment lipid profiles because lipid-modifying medication was commonly used. Furthermore, we had to limit analyses of monocyte subset-specific lipid handling to a subgroup of patients due to technically challenging, time-consuming, and costly methods.
Conclusions
Our data demonstrate an association between low levels of cholesterol efflux mediators and high intermediate monocyte counts, which in turn predicted subsequent cardiovascular events in CKD. Together, our experimental and clinical findings might suggest that increasing Apo A-I concentrations or restoring HDL-C functionality could be an attractive means to modulate skewed monocyte subset distribution and influence monocyte subset counts in CKD. 
